JAK抑制剂治疗类风湿关节炎的序贯疾病活动度评估预测未来治疗轨迹
该多中心注册研究纳入843例接受JAK抑制剂治疗的类风湿关节炎患者,用基于组的轨迹模型识别52周CDAI轨迹,并在第4周和第12周进行landmark分析。早期CDAI绝对值较变化斜率更能预测有利轨迹,第4周和第12周最佳CDAI阈值分别为12.0和9.3。
要点
- 识别出4种CDAI轨迹:快速应答、部分应答伴持续残留活动、高基线活动应答、持续无应答。
- 第52周缓解率在各轨迹组间为0.0%至47.7%。
- 第4周和第12周CDAI绝对值预测有利轨迹优于CDAI斜率。
核心结论
- 早期疾病活动度可动态优化对JAK抑制剂治疗RA患者未来治疗轨迹的预测。
研究设计与样本
- 多中心注册研究,纳入843例接受JAK抑制剂治疗的类风湿关节炎患者,采用基于组的轨迹模型识别52周CDAI轨迹,并在第4周和第12周进行landmark分析。
主要发现
- 识别出4种CDAI轨迹:快速应答者占64.9%,部分应答伴持续残留疾病活动者占18.1%,高基线疾病活动应答者占12.7%,持续无应答者占4.3%。
- 第52周缓解率在各轨迹组间范围为0.0%至47.7%。
- 纳入landmark时间点CDAI显著改善对有利轨迹的预测,而CDAI斜率仅提供极小额外预测价值。
- 纳入第12周CDAI后Brier评分明显改善,进一步纳入CDAI斜率后改善极小。
- Bootstrap验证显示乐观度极小且校准良好。
关键数值与推荐
- 预测有利轨迹的最佳CDAI阈值在第4周为12.0,在第12周为9.3。
临床怎么用
- 支持序贯疾病活动度评估用于时间锚定的治疗决策,早期CDAI绝对值较变化指标更有信息价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to identify disease activity trajectories in patients with rheumatoid arthritis (RA) treated with Janus kinase (JAK) inhibitors and to determine whether early disease activity improved prediction of long-term treatment trajectories. METHODS: We analysed 843 patients treated with JAK inhibitors from a multicentre registry. Group-based trajectory modelling was used to identify distinct Clinical Disease Activity Index (CDAI) trajectories over 52 weeks. Landmark analyses at weeks 4 and 12 were performed using multivariate logistic regression with multiple imputations. Model performance was evaluated using the area under the receiver operating characteristic curve, Brier score, and bootstrap-based internal validation. RESULTS: Four distinct trajectory groups were identified: rapid responders (64.9%), partial responders with persistent residual disease activity (18.1%), responders with high baseline disease activity (12.7%), and persistent nonresponders (4.3%). Week-52 remission rates ranged from 0.0% to 47.7% across the groups. Incorporating the CDAI at landmark time points substantially improved the prediction of a favourable trajectory, whereas the CDAI slope provided minimal additional predictive value. Brier scores improved markedly after incorporating week-12 CDAI, with minimal further improvement after CDAI slope inclusion. Bootstrap validation demonstrated minimal optimism and good calibration. The optimal CDAI thresholds for predicting a favourable trajectory were 12.0 and 9.3 at weeks 4 and 12, respectively. CONCLUSIONS: Early disease activity dynamically refined the prediction of future treatment trajectories in patients with RA treated with JAK inhibitors. The absolute CDAI at landmark time points was more informative than change-based metrics, supporting sequential disease activity assessment for time-anchored treatment decision-making.
引用
- Terabe K, Asai S, Yoshioka Y, et al. Sequential disease activity assessment for predicting future treatment trajectories in patients with rheumatoid arthritis treated with JAK inhibitors: a group-based trajectory and landmark analysis. Ann Rheum Dis. 2026. PMID: 42722589. doi:10.1016/j.ard.2026.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。